SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is trending following its latest update, which showcased substantial revenue growth and accelerating global expansion of its ANKTIVA cancer therapy, sparking community discussion around potential expedited regulatory approvals and a significant short squeeze opportunity amid high after-hours volatility.

Indonesia Energy Corp. Ltd. operates as an oil and gas, exploration, and production company. It engages in oil and gas assets portfolio with a mix between medium-sized producing blocks and exploration blocks with significant resources. Its portfolio includes Kruh, Citarum, and Rangkas Area. The company was founded by James J. Huang and Wirawan Jusuf in 2014 and is headquartered in Jakarta, Indonesia.

Indonesia Energy Corp Ltd

Indonesia Energy Corp Ltd is seeing intense trading and sharp declines despite broader energy sector rallies and surging crude oil prices driven by escalating Middle East tensions. The community is fiercely debating whether this extreme volatility stems from active dilution and market manipulation or is a massive shakeout positioning the low-float stock for a potential short squeeze, reminiscent of its historical explosive movements during geopolitical events.

CrowdStrike Holdings, Inc. provides cybersecurity products and services to stop breaches. It offers cloud-delivered protection across endpoints, cloud workloads, identity and data, and threat intelligence, managed security services, IT operations management, threat hunting, Zero Trust identity protection, and log management. CrowdStrike serves customers worldwide. The company was founded by George P. Kurtz, Gregg Marston, and Dmitri Alperovitch on November 7, 2011 and is headquartered in Austin, TX.

Crowdstrike Holdings Inc - Ordinary Shares - Class A

Crowdstrike Holdings Inc

Crowdstrike is trending following its recent earnings report, which delivered a narrow beat and generally in-line guidance, sparking a heated community debate between those who view it as a leading cybersecurity platform poised to benefit from AI and rising geopolitical tensions, and others who contend its valuation remains excessively high despite analyst upgrades.

GitLab, Inc. engages in the intelligent DevSecOps platform for software innovation. The firm enables organizations to increase developer productivity, improve operational efficiency, reduce security and compliance risk, and accelerate digital transformation. The company was founded by Dmitriy Zaporozhets and Sid Sijbrandij in 2011 and is headquartered in San Francisco, CA.

Gitlab Inc - Ordinary Shares - Class A

Gitlab Inc

GitLab is trending following mixed reactions to its Q4 '26 earnings report, which saw a beat on revenue and EPS along with a $400M share repurchase program, yet offered weaker-than-expected FY2027 guidance. The community is divided between those buying the dip, citing AI integration and persistent buyout rumors, and bears concerned about slowing growth and the impact of AI competition on software companies.

Aurinia Pharmaceuticals, Inc. is a clinical stage bio-pharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Edmonton, Canada.

Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals is trending following a strong earnings beat and robust cash position, yet community discussion is overwhelmingly dominated by frustration over CEO Peter Greenleaf's continued lack of transparency regarding AUR200's clinical trial indications, fueling speculation of an imminent buyout amidst accusations of mismanagement.

Kraken Robotics, Inc. engages in the design, manufacture, and sale of software-centric sensors, subsea batteries, thrusters and underwater robotic systems. It operates through the following geographical segments: Asia Pacific, Europe, Middle East and Africa, North America, and Other. The company was founded on May 14, 2008, and is headquartered in Mt. Pearl, Canada.

Kraken Robotics Inc

Kraken Robotics Inc. is trending following its transformative acquisition of Covelya Group, significantly expanding its global footprint in subsea technology and positioning it as a major supplier for defense and commercial sectors. The community is actively discussing potential short-term share dilution from a public offering against robust long-term growth potential and strategic partnerships within the burgeoning underwater robotics sector.

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

Moderna is surging amid a flurry of positive developments, including a significant settlement in its patent dispute with Arbutus Biopharma and Genevant, the FDA's reversal to review its seasonal flu vaccine, and a European recommendation for its COVID-19/flu combination shot, driving strong community optimism for its pipeline and a potential short squeeze.

Venture Global, Inc. engages in the development and construction of liquefied natural gas production, establishing us as a rapidly growing company delivering critical LNG to the world. It projects include Calcasieu, Plaquemines, CP2, CP3 and Delta projects. The company was founded by Michael Sabel and Robert Pender in 2023 and is headquartered in Arlington, VA.

Venture Global Inc. - Ordinary Shares - Class A

Venture Global Inc

Venture Global is surging as escalating Middle East tensions halt Qatar's LNG production and disrupt the Strait of Hormuz, driving global natural gas prices dramatically higher. This geopolitical "perfect storm," combined with a strong earnings beat and a favorable legal outcome against Shell, positions the company as a key beneficiary, fueling community discussion around potential short squeezes and its undervalued status.

Ross Stores, Inc. engages in the operation of off-price retail apparel and home accessories stores. Its products include branded and designer apparel, accessories, footwear, and home fashions through the Dress for Less and dd's DISCOUNTS brands. The company was founded by Stuart G. Moldaw in 1957 and is headquartered in Dublin, CA.

Ross Stores, Inc.

Ross Stores is trending after reporting strong financial results, surpassing expectations for the recent quarter, and projecting solid sales and earnings growth for the upcoming fiscal years, alongside a significant share buyback program. The community is actively discussing whether these positive results and outlook justify the stock's current valuation, given broader retail market dynamics.

Rigel Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It discovers and develops novel, targeted drugs in the therapeutic areas of immunology, oncology and immune oncology. The firm focuses on intracellular signalling pathways and related targets that are critical to disease mechanisms. The company's products include Tavalisse, Fostamatinib and R835. Rigel Pharmaceuticals was founded by Donald G. Payan, James M. Gower, Thomas A. Raffin, Garry P. Nolan and Ronald B. Garren on June 14, 1996 and is headquartered in South San Francisco, CA.

Rigel Pharmaceuticals

Rigel Pharmaceuticals is trending due to preliminary Q4 financial results surpassing expectations, confirming profitability and strong product sales growth. This, alongside promising clinical data for its pipeline assets and an active biotech M&A landscape, fuels widespread community speculation about the company's significant undervaluation and potential for a strategic acquisition, despite persistent short interest.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Roubaix Capital LLC Invests $2.16 Million in UiPath, Inc. $PATH

Roubaix Capital LLC bought a new stake in UiPath, Inc. (NYSE:PATH - Free Report) in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm...

Quantbot Technologies LP Invests $6.91 Million in UiPath, Inc. $PATH

Quantbot Technologies LP purchased a new stake in shares of UiPath, Inc. (NYSE:PATH - Free Report) during the 3rd quarter, according to its most recent Form 13F filing with the Securities and...

UiPath's Debt-Free Balance Sheet Fuels Strategic Flexibility

PATH's debt-free balance sheet and $1.4B cash reserve give it unique flexibility to invest boldly in automation growth.

Oversold Conditions For UiPath (PATH)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a...

UiPath, Inc. (PATH) Is a Trending Stock: Facts to Know Before Betting on It

Zacks.com users have recently been watching UiPath (PATH) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Stock Market Today, Feb. 26: UiPath Advances as It Moves to Shape Agentic AI Standards

UiPath (NYSE:PATH), a company that creates AI and automation software for complex processes, closed Thursday at $10.71, up 7.75%. The stock rose as investors responded to its Agentic AI Foundation...

Citigroup Inc. Sells 1,899,713 Shares of UiPath, Inc. $PATH

Citigroup Inc. decreased its holdings in UiPath, Inc. (NYSE:PATH - Free Report) by 43.6% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission...

Workday (WDAY) Beats Q4 Earnings and Revenue Estimates

Workday (WDAY) delivered earnings and revenue surprises of +7.21% and +0.36%, respectively, for the quarter ended January 2026. Do the numbers hold clues to what lies ahead for the stock?

UiPath Joins Agentic AI Foundation (AAIF) to Advance Interoperability in Agentic AI Adoption

UiPath (NYSE: PATH), a global leader in agentic automation, today announced it has joined the Agentic AI Foundation (AAIF) as a Gold Member. Together with other member organizations, UiPath will work...

Coherent vs. UiPath: Which AI Growth Stock Is the Better Buy?

AI-fueled growth, surging revenues and bold partnerships set up a showdown, but which stock among COHR and PATH has the stronger edge? Read on to find out.

UiPath, Inc. engages in the development and provision of a software platform to automate business processes. The firm serves the public, healthcare, telecommunication, finance, and banking industries. It also offers accounts payable automation, claims processing automation, contact center automation, and finance and accounting automation. The company was founded by Daniel Dines and Marius Tirca in 2005 and is headquartered in New York, NY.

UiPath Inc - Ordinary Shares - Class A

Software / SaaS

Cybersecurity

Cloud Infrastructure

AI / Semiconductors

Which beaten-down sector are you buying first?

Stocktwits

Stocktwits Polls

UiPath Inc

Traders are eagerly awaiting earnings, forecasting a significant beat on Q4 revenue (est. $472M-$478M) and EPS (est. $0.27-$0.29), with positive new guidance and ARR growth expected.

A high short interest of over 23% has fueled speculation among traders about an imminent short squeeze that could propel the stock much higher.

Discussions focus on the company's expansion into agentic AI solutions, particularly in healthcare, amidst a competitive landscape and debates over its long-term impact on RPA.

Traders are closely watching key resistance levels at $10.83 and $11.60, hoping for a decisive move to break through to $12 before the upcoming earnings report.

The stock has shown surprising resilience by staying green on days when the broader market is red, prompting many investors to "buy the dip" and accumulate shares.

Current Price	$11.04
Prev Close	$10.70
Open	$10.45
Dividend Yield	0.00%
50-Day Moving Average	$13.98
Beta	1.82
Avg. Volume	34.98M
PE Ratio	25.24

52-Week High	$19.84
52-Week Low	$9.38
Market Capitalization	$6.12B
EPS (Annual)	-$0.1316
Price to Book	2.97
Revenue Per Employee	$369,613.24

PATH
UiPath Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest PATH News

PATHUiPath Inc